A Look At Thermo Fisher Scientific (TMO) Valuation After Q1 Earnings And Cautious Outlook

Thermo Fisher Scientific (TMO) shares declined after Q1 2026 earnings, despite revenue reaching US$11.01b and GAAP diluted EPS of US$4.43, as the company issued lighter guidance due to macroeconomic pressures. The company is considered 13.4% undervalued with a fair value of $540.27 compared to its current price of $468.04, supported by R&D expansion, emerging market growth, and M&A. Investors are encouraged to assess the risks, such as weaker biotech and pharma R&D funding, against the potential rewards.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin